Taris Biomedical LLC

scPharmaceuticals Inc., based in Lexington, MA, is dedicated to advancing cardiorenal innovation through integrated treatments designed to address unmet patient needs in cardiovascular and renal care. The company focuses on pioneering patient-centric approaches that enhance health outcomes, reduce burdens, and improve the quality of life for individuals suffering from heart failure and chronic kidney disease. With a commitment to developing drug-device combinations and value-based treatments, scPharmaceuticals positions itself as a trusted leader in the industry, continuously striving to redefine healthcare standards. Their flagship product, FUROSCIX, represents a significant step forward in empowering health and transforming lives within the cardiorenal space. Generated from the website

Lyndra Therapeutics, founded in 2015 from technology developed in the Langer Lab at MIT, is dedicated to revolutionizing medicine by creating long-acting oral therapies. Their innovative LYNX drug delivery platform aims to simplify medication routines for patients, reducing the frequency of pill intake to once a week or even once a month. The company's mission centers around improving patient experiences and enhancing health outcomes through groundbreaking advancements in drug delivery systems. With a diverse team of experts from various fields, Lyndra is positioned to address multiple therapeutic areas and transform the landscape of oral medications. Generated from the website

Shire Specialty Pharmaceuticals is a division of Shire, which offers products under the VYVANSE, DAYTRANA, ADDERALL, FOSRENOL, AGRYLIN, ELAPRASE and PENTASA brand names for the treatment attention deficit hyperactivity disorder. The division sells its products to several pharmaceutical wholesale distributors and pharmacies in the United States and Europe. Founded in 1994, Shire is one of the leading specialty biopharmaceutical companies that focuses on meeting the needs of specialist physicians in Pennsylvania. The parent company has a staff of more than 1,600 employees. Shire s subsidiaries include Shire Human Genetic Therapies UK Limited, Shire Human Genetic Therapies Securities Corporation, Shire Investments & Finance (U.K.) Company, Shire Pharmaceutical Contracts Limited and Shire Intellectual Property 2 SRL.